Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  4/6/2018
Valeant Site 05
mi
from
Austin, TX
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 4/6/2018
Valeant Site 05
mi
from
Austin, TX
Click here to add this to my saved trials
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  4/6/2018
Valeant Site 01
mi
from
Houston, TX
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 4/6/2018
Valeant Site 01
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  4/6/2018
Valeant Site 12
mi
from
Norfolk, VA
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 4/6/2018
Valeant Site 12
mi
from
Norfolk, VA
Click here to add this to my saved trials
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  4/6/2018
Valeant Site 15
mi
from
Spokane, WA
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 4/6/2018
Valeant Site 15
mi
from
Spokane, WA
Click here to add this to my saved trials
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  4/6/2018
Valeant Site 13
mi
from
Clinton Township, MI
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 4/6/2018
Valeant Site 13
mi
from
Clinton Township, MI
Click here to add this to my saved trials
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  4/6/2018
Valeant Site 5
mi
from
Fremont, CA
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 4/6/2018
Valeant Site 5
mi
from
Fremont, CA
Click here to add this to my saved trials
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  4/6/2018
Valeant Site 3
mi
from
Boynton Beach, FL
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 4/6/2018
Valeant Site 3
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  4/6/2018
Valeant Site 11
mi
from
North Miami Beach, FL
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 4/6/2018
Valeant Site 11
mi
from
North Miami Beach, FL
Click here to add this to my saved trials
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  4/6/2018
Valeant Site 16
mi
from
Warren, MI
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 4/6/2018
Valeant Site 16
mi
from
Warren, MI
Click here to add this to my saved trials
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  4/6/2018
Valeant Site 07
mi
from
Fridley, MN
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 4/6/2018
Valeant Site 07
mi
from
Fridley, MN
Click here to add this to my saved trials
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  4/6/2018
Valeant Site 01
mi
from
East Windsor, NJ
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 4/6/2018
Valeant Site 01
mi
from
East Windsor, NJ
Click here to add this to my saved trials
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  4/6/2018
Valeant Site 4
mi
from
Albuquerque, NM
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 4/6/2018
Valeant Site 4
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  4/6/2018
Valeant Site 03
mi
from
New York, NY
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 4/6/2018
Valeant Site 03
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  4/6/2018
Valeant Site 02
mi
from
High Point, NC
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 4/6/2018
Valeant Site 02
mi
from
High Point, NC
Click here to add this to my saved trials
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  4/6/2018
Valeant Site 5
mi
from
Portland, OR
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 4/6/2018
Valeant Site 5
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  4/6/2018
Valeant Site 7
mi
from
Knoxville, TN
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 4/6/2018
Valeant Site 7
mi
from
Knoxville, TN
Click here to add this to my saved trials
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  4/6/2018
Valeant Site 06
mi
from
College Station, TX
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 4/6/2018
Valeant Site 06
mi
from
College Station, TX
Click here to add this to my saved trials
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  4/6/2018
Valeant Site 01
mi
from
Houston, TX
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 4/6/2018
Valeant Site 01
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  4/6/2018
Valeant Site 20
mi
from
Pflugerville, TX
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 4/6/2018
Valeant Site 20
mi
from
Pflugerville, TX
Click here to add this to my saved trials
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  4/6/2018
Valeant Site 34
mi
from
Detroit, MI
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 4/6/2018
Valeant Site 34
mi
from
Detroit, MI
Click here to add this to my saved trials
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/11/2018
1220.19.0007 Boehringer Ingelheim Investigational Site
mi
from
Palm Desert, CA
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/11/2018
1220.19.0007 Boehringer Ingelheim Investigational Site
mi
from
Palm Desert, CA
Click here to add this to my saved trials
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/11/2018
1301.1.5807 Boehringer Ingelheim Investigational Site
mi
from
Upland, CA
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/11/2018
1301.1.5807 Boehringer Ingelheim Investigational Site
mi
from
Upland, CA
Click here to add this to my saved trials
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/11/2018
1199.15.10027 Boehringer Ingelheim Investigational Site
mi
from
Tampa, FL
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/11/2018
1199.15.10027 Boehringer Ingelheim Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/11/2018
1245.23.10148 Boehringer Ingelheim Investigational Site
mi
from
Lexington, KY
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/11/2018
1245.23.10148 Boehringer Ingelheim Investigational Site
mi
from
Lexington, KY
Click here to add this to my saved trials
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/11/2018
1200.45.066 Boehringer Ingelheim Investigational Site
mi
from
Freehold, NJ
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/11/2018
1200.45.066 Boehringer Ingelheim Investigational Site
mi
from
Freehold, NJ
Click here to add this to my saved trials
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/11/2018
1301.1.5557 Boehringer Ingelheim Investigational Site
mi
from
Duncansville, PA
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/11/2018
1301.1.5557 Boehringer Ingelheim Investigational Site
mi
from
Duncansville, PA
Click here to add this to my saved trials
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/11/2018
Boehringer Ingelheim Investigational Site
mi
from
Charleston, SC
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/11/2018
Boehringer Ingelheim Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/11/2018
1160.129.32338 Boehringer Ingelheim Investigational Site
mi
from
Jackson, TN
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/11/2018
1160.129.32338 Boehringer Ingelheim Investigational Site
mi
from
Jackson, TN
Click here to add this to my saved trials
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/11/2018
1270.1.32001 Boehringer Ingelheim Investigational Site
mi
from
Bruxelles,
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/11/2018
1270.1.32001 Boehringer Ingelheim Investigational Site
mi
from
Bruxelles,
Click here to add this to my saved trials
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/11/2018
1199.14.1158 Boehringer Ingelheim Investigational Site
mi
from
Seattle, WA
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/11/2018
1199.14.1158 Boehringer Ingelheim Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
Status: Enrolling
Updated:  4/11/2018
Clinical Research Facility
mi
from
Tampa, FL
A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
Status: Enrolling
Updated: 4/11/2018
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
Status: Enrolling
Updated:  4/11/2018
Clinical Research Facility
mi
from
Carmel, IN
A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
Status: Enrolling
Updated: 4/11/2018
Clinical Research Facility
mi
from
Carmel, IN
Click here to add this to my saved trials
A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
Status: Enrolling
Updated:  4/11/2018
Clinical Research Facility
mi
from
Plainfield, IN
A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
Status: Enrolling
Updated: 4/11/2018
Clinical Research Facility
mi
from
Plainfield, IN
Click here to add this to my saved trials
A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
Status: Enrolling
Updated:  4/11/2018
Clinical Research Facility
mi
from
Albuquerque, NM
A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
Status: Enrolling
Updated: 4/11/2018
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
Status: Enrolling
Updated:  4/11/2018
Clinical Research Facility
mi
from
High Point, NC
A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
Status: Enrolling
Updated: 4/11/2018
Clinical Research Facility
mi
from
High Point, NC
Click here to add this to my saved trials
A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis
A Phase Ib/IIa, Multiple-Dose, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Mild to Moderate Atopic Dermatitis
Status: Enrolling
Updated:  4/26/2018
Comprehensive Phase One
mi
from
Miramar, FL
A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis
A Phase Ib/IIa, Multiple-Dose, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Mild to Moderate Atopic Dermatitis
Status: Enrolling
Updated: 4/26/2018
Comprehensive Phase One
mi
from
Miramar, FL
Click here to add this to my saved trials
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated:  5/2/2018
Boehringer Ingelheim Investigational Site
mi
from
Birmingham, AL
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated: 5/2/2018
Boehringer Ingelheim Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated:  5/2/2018
1311.28.10029 Boehringer Ingelheim Investigational Site
mi
from
Rogers, AR
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated: 5/2/2018
1311.28.10029 Boehringer Ingelheim Investigational Site
mi
from
Rogers, AR
Click here to add this to my saved trials
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated:  5/2/2018
1220.48.0008 Boehringer Ingelheim Investigational Site
mi
from
Bakersfield, CA
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated: 5/2/2018
1220.48.0008 Boehringer Ingelheim Investigational Site
mi
from
Bakersfield, CA
Click here to add this to my saved trials
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated:  5/2/2018
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated: 5/2/2018
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated:  5/2/2018
1160.189.11272 Boehringer Ingelheim Investigational Site
mi
from
Pasadena, CA
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated: 5/2/2018
1160.189.11272 Boehringer Ingelheim Investigational Site
mi
from
Pasadena, CA
Click here to add this to my saved trials
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated:  5/2/2018
1160.129.32687 Boehringer Ingelheim Investigational Site
mi
from
Ventura, CA
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated: 5/2/2018
1160.129.32687 Boehringer Ingelheim Investigational Site
mi
from
Ventura, CA
Click here to add this to my saved trials
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated:  5/2/2018
1275.1.01110 Boehringer Ingelheim Investigational Site
mi
from
Coral Gables, FL
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated: 5/2/2018
1275.1.01110 Boehringer Ingelheim Investigational Site
mi
from
Coral Gables, FL
Click here to add this to my saved trials
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated:  5/2/2018
205.452.01135 Boehringer Ingelheim Investigational Site
mi
from
Ormond Beach, FL
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated: 5/2/2018
205.452.01135 Boehringer Ingelheim Investigational Site
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated:  5/2/2018
1200.45.095 Boehringer Ingelheim Investigational Site
mi
from
Alpharetta, GA
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated: 5/2/2018
1200.45.095 Boehringer Ingelheim Investigational Site
mi
from
Alpharetta, GA
Click here to add this to my saved trials
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated:  5/2/2018
Boehringer Ingelheim Investigational Site
mi
from
Chicago, IL
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated: 5/2/2018
Boehringer Ingelheim Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated:  5/2/2018
1199.14.1152 Boehringer Ingelheim Investigational Site
mi
from
Indianapolis, IN
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated: 5/2/2018
1199.14.1152 Boehringer Ingelheim Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated:  5/2/2018
1268.17.01025 Boehringer Ingelheim Investigational Site
mi
from
South Bend, IN
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated: 5/2/2018
1268.17.01025 Boehringer Ingelheim Investigational Site
mi
from
South Bend, IN
Click here to add this to my saved trials
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated:  5/2/2018
1222.29.11002 Boehringer Ingelheim Investigational Site
mi
from
Overland Park, KA
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated: 5/2/2018
1222.29.11002 Boehringer Ingelheim Investigational Site
mi
from
Overland Park, KA
Click here to add this to my saved trials
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated:  5/2/2018
205.440.1003 Boehringer Ingelheim Investigational Site
mi
from
Boston, MA
BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Status: Enrolling
Updated: 5/2/2018
205.440.1003 Boehringer Ingelheim Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials